Antares Pharma, Inc. ATRS
Apr 24, 2025, 3:47 PM EDT
52-week range unavailable
- Market cap
- 955.06M
- Revenue (ttm)
- 183.46M
- Profit margin
- 21.90%
- Shares out
- 170.85M
- Forward P/E
- 25.41
- Volume
- 1.76M
- Open
- 5.59
- Previous close
- 5.59
- Day's range
- 5.58 – 5.59
- Beta
- 1.15
- Analysts
- Hold
- Price target
- 5.95 (+6.4%)
- Earnings date
- May 10, 2022
2Y +1.93 (+52.73%)
Key statistics
- Enterprise value
- 918.34M
- PEG ratio
- 0.89
- Price / sales
- 5.21
- Price / book
- 5.43
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -1.30%
- Free cash flow
- -19.87M
- Total cash
- 62.21M
- Total debt
- 25.49M
- Return on equity
- 26.61%
- Short % of float
- 2.86%
- 50-day average
- 4.90
- 200-day average
- 3.92
Analyst view
Consensus: hold
- Target (low)
- 5.60
- Target (mean)
- 5.95
- Target (high)
- 7.00
- Strong buy3
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
May 10, 2022
Expected May 10, 2022. Consensus EPS estimate 0.01.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 10, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Mar 3, 2022 | Dec 1, 2021 | 0.01 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | 0.03 | — | — | — |
| Aug 5, 2021 | Jun 1, 2021 | 0.02 | — | — | — |
| May 6, 2021 | Mar 1, 2021 | 0.02 | — | — | — |
| Mar 2, 2021 | Dec 1, 2020 | 0.04 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 14, 2022 | Truist Securities | down | Buy | Hold |
| Apr 14, 2022 | Ladenburg Thalmann | down | Buy | Neutral |
| Apr 14, 2022 | Raymond James | down | Strong Buy | Market Perform |
| Apr 14, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Apr 14, 2022 | Piper Sandler | down | Overweight | Neutral |
| Nov 5, 2021 | HC Wainwright & Co. | main | — | Buy |
About Antares Pharma, Inc.
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- antarespharma.com
News
Antares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last? 
Antares Pharma Inc shares up 45% on Wednesday: how come? 
Why Antares Pharma Stock Is Soaring Today 
Why Is Antares Pharma (ATRS) Stock Up Today? 
Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes 
Why Antares Pharma Stock Is Bolting Higher Today 
Antares Pharma stock rockets after Halozyme buyout deal for a near-50% premium 
Antares Pharma's Oral Testosterone Treatment Scores FDA Approval 
Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q4 2021 Results - Earnings Call Transcript 
Antares Pharma (ATRS) Surpasses Q4 Earnings and Revenue Estimates
Your note
Sign in to keep a note on ATRS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| APPLE ROBERT F | Chief Executive Officer | Stock Award(Grant) | Mar 2, 2022 | 2,488,360 |
| GARRITY THOMAS JOHN | Director | Stock Award(Grant) | Jun 9, 2021 | 249,858 |
| GRAHAM PETER J | General Counsel | Stock Award(Grant) | Mar 2, 2022 | 616,609 |
| GREENLEAF PETER S | Director | Stock Award(Grant) | Jun 9, 2021 | 79,645 |
| GUETH ANTON G | Director | Sale | Jul 7, 2021 | 467,577 |
| JACOB LEONARD S | Director | Stock Gift | Oct 25, 2021 | 170,575 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.00% | 11,954,171 | 49.01M | Mar 30, 2022 |
| Rubric Capital Management LP | 6.38% | 10,900,000 | 44.69M | Mar 30, 2022 |
| Vanguard Group, Inc. (The) | 5.06% | 8,643,155 | 35.44M | Mar 30, 2022 |
| Sargent Investment Group, LLC | 2.14% | 3,663,275 | 15.02M | Mar 30, 2022 |
| Amundi | 2.02% | 3,451,789 | 14.15M | Mar 30, 2022 |
| State Street Corporation | 2.02% | 3,449,457 | 14.14M | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.69% | 4,597,597 | 16.41M | Dec 30, 2021 |
| iShares Russell 2000 ETF | 2.22% | 3,796,979 | 13.29M | Feb 27, 2022 |
| Vanguard Extended Market Index Fund | 1.21% | 2,059,033 | 7.35M | Dec 30, 2021 |
| iShares Russell 2000 Growth ETF | 0.82% | 1,395,324 | 5.72M | Mar 30, 2022 |
| Fidelity Small Cap Index Fund | 0.75% | 1,283,472 | 4.49M | Feb 27, 2022 |
| Fidelity Extended Market Index Fund | 0.52% | 892,056 | 3.12M | Feb 27, 2022 |